Search Results

You are looking at 151 - 160 of 2,880 items for :

  • Refine by Access: All x
Clear All
Full access

Relationship Between Perceptions of Treatment Goals and Psychological Distress in Patients With Advanced Cancer

Areej El-Jawahri, Deborah Forst, Alyssa Fenech, Keri O. Brenner, Amanda L. Jankowski, Lauren Waldman, Isabella Sereno, Ryan Nipp, Joseph A. Greer, Lara Traeger, Vicki Jackson, and Jennifer Temel

their cancer. Figure 1. Patients’ perceptions of their treatment goal and of their oncologist’s goal. Association Between Patients’ Perceptions of Treatment Goals and Patient-Reported Outcomes Figures 2 and 3 depict the rates of clinically significant

Full access

Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review

Andrew J. Portuguese, Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson, and Evan T. Hall

are now eligible for treatment with ICIs. 8 Due to the need for chronic immunosuppressive therapy, SOTRs with cancer have been consistently excluded from clinical trials with ICIs. 9 – 16 Thus, clinical outcomes for cancers arising in SOTRs treated

Full access

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes

Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong

and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma

Full access

Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag, and Tanios Bekaii-Saab

Background Nodal status has long been considered a key pathologic factor in cancer management and care. Previous studies have demonstrated an association between lymph node yield and status with regard to patient outcomes in colorectal cancer

Full access

Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis

Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li

recurrence, leading to a poor prognosis. 4 Therefore, there is an urgent need for adjuvant treatment intensification to prevent disease recurrence and improve survival outcomes. Currently, mitotane monotherapy, cytotoxic drugs, and radiotherapy (RT) are

Full access

Enrollment Criteria Controversies for Active Surveillance and Triggers for Conversion to Treatment in Prostate Cancer

David D. Buethe and Julio Pow-Sang

remains to optimize the criteria that qualify a man as either low risk or very low risk, and to establish standardized criteria defining disease progression. Further, there is a paucity of reports on the long-term outcomes of men electing to delay or forgo

Full access

Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance

P. Travis Courtney, Rishi Deka, Nikhil V. Kotha, Daniel R. Cherry, Mia A. Salans, Tyler J. Nelson, Abhishek Kumar, Elaine Luterstein, Anthony T. Yip, Vinit Nalawade, J. Kellogg Parsons, A. Karim Kader, Tyler F. Stewart, and Brent S. Rose

studies of AS in intermediate-risk disease have been limited by small sample sizes, short follow-up, and lack of definitive clinical outcomes, including metastasis and prostate cancer–specific mortality (PCSM). 5 – 12 Nevertheless, the use of AS in

Full access

Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response

Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang

Background Immune checkpoint inhibitor (ICI) therapy significantly improves cancer outcomes by targeting CLTA-4 or PD-1/L1 and boosting T-cell–mediated immune responses and antitumor effects. 1 , 2 ICIs are widely used as first-line therapy

Full access

Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis

Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin

most patients with UCRP are elderly and many have had prior radical nephroureterectomy, the concern for renal toxicity frequently limits the use of these chemotherapeutic regimens. 11 The poor outcomes and significant toxicities associated with first

Full access

CLO22-048: Treatment Outcomes of Metastatic Urothelial Cancer on Immune Checkpoint Inhibition

Aruni Ghose, John Hayes, Nicolas Omorphos, Nikhil Vasdev, and Sharma Anand

revolutionised the treatment landscape. There exists a dearth of literature of real-world data on clinical trials focussing on immunotherapy treatment outcomes. Methods : Our study population included mUC patients treated at two large North West London Cancer